Bausch Health Companies (BHC) Other Non-Current Assets (2009 - 2026)
Bausch Health Companies (BHC) reported Other Non-Current Assets of $369.0 million for Q1 2026, down 2.89% on a YoY basis from $380.0 million in Q1 2025, and down 2.38% sequentially from $378.0 million in Q4 2025.
Bausch Health Companies (BHC) Other Non-Current Assets (2009 - 2026) Analysis & Trends
Bausch Health Companies (BHC) has 18 years of Other Non-Current Assets data on file, last reported at $369.0 million in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Assets fell 2.89% year-over-year to $369.0 million; the trailing twelve-month figure through Mar 2026 stood at $369.0 million (down 2.89% YoY), and the FY2025 full-year result was $378.0 million, up 4.13% from the prior year.
- Other Non-Current Assets slipped to $369.0 million in Q1 2026, from $378.0 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $389.0 million in Q3 2024 to a low of $307.0 million in Q4 2023.
- A 5-year average of $347.5 million and a median of $338.0 million in 2022 frame the typical range for Other Non-Current Assets.
- Across the five-year window, Other Non-Current Assets sank 45.87% in 2022 and advanced 21.79% in 2025, its largest moves.
- Tracing BHC's Other Non-Current Assets over 5 years: stood at $326.0 million in 2022, then declined by 5.83% to $307.0 million in 2023, then advanced by 18.24% to $363.0 million in 2024, then climbed by 4.13% to $378.0 million in 2025, then decreased by 2.38% to $369.0 million in 2026.
- Business Quant data shows BHC's Other Non-Current Assets at $369.0 million in Q1 2026, $378.0 million in Q4 2025, and $382.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 49.22 Mn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 1.79 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 351.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 491.06 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 233.20 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.11 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 73.60 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 295.00 Mn |
| 10 | Bausch Health Companies | 1.66 Bn | 1.33 Bn | 2.52 Bn | 369.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 369.00 Mn |
| Dec 31, 2025 | 378.00 Mn |
| Sep 30, 2025 | 382.00 Mn |
| Jun 30, 2025 | 388.00 Mn |
| Mar 31, 2025 | 380.00 Mn |
| Dec 31, 2024 | 363.00 Mn |
| Sep 30, 2024 | 389.00 Mn |
| Jun 30, 2024 | 329.00 Mn |
| Mar 31, 2024 | 312.00 Mn |
| Dec 31, 2023 | 307.00 Mn |
| Sep 30, 2023 | 328.00 Mn |
| Jun 30, 2023 | 325.00 Mn |
| Mar 31, 2023 | 318.00 Mn |
| Dec 31, 2022 | 326.00 Mn |
| Sep 30, 2022 | 341.00 Mn |
| Jun 30, 2022 | 338.00 Mn |
| Mar 31, 2022 | 334.00 Mn |
| Dec 31, 2021 | 340.00 Mn |
| Sep 30, 2021 | 343.00 Mn |
| Jun 30, 2021 | 596.00 Mn |